GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (FRA:IDD) » Definitions » Accumulated other comprehensive income (loss)

Innate Pharma (FRA:IDD) Accumulated other comprehensive income (loss) : €0.35 Mil (As of Jun. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Innate Pharma Accumulated other comprehensive income (loss)?

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings. Innate Pharma's Accumulated other comprehensive income (loss) for the quarter that ended in Jun. 2024 was €0.35 Mil.

Innate Pharma's quarterly Accumulated other comprehensive income (loss) declined from Jun. 2023 (€1.06 Mil) to Dec. 2023 (€0.50 Mil) and declined from Dec. 2023 (€0.50 Mil) to Jun. 2024 (€0.35 Mil).

Innate Pharma's annual Accumulated other comprehensive income (loss) increased from Dec. 2021 (€0.46 Mil) to Dec. 2022 (€0.82 Mil) but then declined from Dec. 2022 (€0.82 Mil) to Dec. 2023 (€0.50 Mil).

Innate Pharma Accumulated other comprehensive income (loss) Historical Data

The historical data trend for Innate Pharma's Accumulated other comprehensive income (loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Accumulated other comprehensive income (loss) Chart

Innate Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accumulated other comprehensive income (loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.47 0.36 0.46 0.82 0.50

Innate Pharma Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Accumulated other comprehensive income (loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.28 0.82 1.06 0.50 0.35

Innate Pharma Accumulated other comprehensive income (loss) Calculation

Accumulated other comprehensive income (loss) is the aggregate amount of gains or losses that are not part of retained earnings.

Innate Pharma Accumulated other comprehensive income (loss) Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Accumulated other comprehensive income (loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (FRA:IDD) » Definitions » Accumulated other comprehensive income (loss)
Comparable Companies
XPAR:ADOC XPAR:IVA XPAR:TNG XPAR:ALCLS XPAR:MAAT XPAR:DBV XPAR:NANO XPAR:OSE XPAR:ALSEN XPAR:AELIS VRTX REGN ASX:CSL XKRX:207940 XBRU:UCB ALNY XBRU:ARGX XKRX:068270 BNTX BGNE
Traded in Other Exchanges
IPHYF:USA IPHA:USA 0EVI:UK IPH:France IDD:Germany
Address
117, Avenue de Luminy, Marseille, FRA, 13009
Website
https://www.innate-pharma.com
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Innate Pharma Headlines

No Headlines